Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV-1 infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection , while five non-neutralizing NTD antibodies mediated FcγR-independent infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Nonetheless, three of 31 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while antibody-enhanced infection does not necessarily herald enhanced infection , increased lung inflammation can occur in SARS-CoV-2 antibody-infused macaques.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805451PMC
http://dx.doi.org/10.1101/2020.12.31.424729DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 neutralizing
8
infection-enhancing antibodies
8
ntd antibodies
8
lung inflammation
8
antibodies
7
sars-cov-2
6
infection
5
functions sars-cov-2
4
neutralizing infection-enhancing
4
antibodies vitro
4

Similar Publications

Background: Covid-19 vaccines are updated to match circulating strains based on reasoning that better strain-matched immunogenicity should provide better protection. Randomized evidence with disease endpoints to support strain matching is lacking. We evaluated COVID-19 incidence among adults randomized to a second booster of Prototype or Omicron-based vaccines.

View Article and Find Full Text PDF

Frequent emergence of respiratory viruses with pandemic potential, like SARS-CoV-2 or influenza, underscores the need for broad-spectrum prophylaxis. Existing vaccines show reduced efficacy against newly emerged variants, and the ongoing risk of new outbreaks highlights the importance of alternative strategies to prevent infection and viral transmission. As respiratory viruses primarily enter through the nose, formulations targeting the nasal epithelium are attractive candidates to neutralize pathogens and thus prevent or minimize infection.

View Article and Find Full Text PDF

The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.

View Article and Find Full Text PDF

New SARS-CoV-2 variants continue to emerge and may cause new waves of COVID-19. Antibody evasion is a major driver of variant emergence but variants can also exhibit altered capacity to enter lung cells and to use ACE2 species orthologues for cell entry. Here, we assessed cell line tropism, usage of ACE2 orthologues and antibody evasion of variant MC.

View Article and Find Full Text PDF

Colloidal gold technology in viral diagnostics: Recent innovations, clinical applications, and future perspectives.

Virology

September 2025

Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China. Electronic address:

Colloidal gold technology has revolutionized viral diagnostics through its rapid, cost-effective, and user-friendly applications, particularly in point-of-care testing (POCT). This review synthesizes recent advancements, focusing on its role in detecting respiratory viruses, hepatitis viruses, and emerging pathogens. The technology leverages the unique optical and physicochemical properties of gold nanoparticles (AuNPs), including localized surface plasmon resonance (LSPR) and high surface-to-volume ratios, to achieve rapid antigen-antibody recognition with visual readouts within 15 min.

View Article and Find Full Text PDF